Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology leader advancing innovative oral therapies for hepatitis B virus (HBV) and microbiome-related disorders. This news hub provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on ASMB's antiviral research programs and microbiome therapeutic platforms. Our curated news collection features press releases covering clinical trial progress, partnership announcements, and scientific presentations - all essential for informed analysis of the company's pipeline.
Key focus areas include updates on HBV core inhibitor candidates, microbiome strain development, and intellectual property advancements. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining scientific accuracy.
Bookmark this page for direct access to primary source materials and objective reporting on ASMB's pioneering work in oral antiviral therapies. Check regularly for the latest developments in this dynamic sector of precision medicine.
Assembly Biosciences (Nasdaq: ASMB) has shared Phase 1a clinical data for its HBV core inhibitor, ABI-4334, which shows promising efficacy against viral replication and cccDNA formation. The company is actively considering partnering options for its core inhibitor portfolio, aiming to advance the development of these therapies. In addition, Assembly Bio is prioritizing its antiviral pipeline, including ABI-5366 for high-recurrence genital herpes, with plans to enter clinical trials in the first half of 2024. The financial outlook remains strong, with an estimated cash runway extending into Q3 2024. CEO Jason Okazaki highlighted the need for longer-duration studies to validate the efficacy of core inhibitors. Overall, the results suggest a strong foundation for future development in HBV treatments.
Assembly Biosciences, Inc. (Nasdaq: ASMB) updated its progress on investigational hepatitis B virus (HBV) core inhibitors ABI-3733 and ABI-4334. The company is prioritizing ABI-4334 based on its superior potency and clinical profile while pausing ABI-3733 due to observed toxicity concerns. Preliminary data from ABI-3733’s Phase 1b trial showed significant viral suppression in patients. Financially, the company reported a net loss of $93.1 million for 2022, an improvement from $129.9 million in 2021. As of December 31, 2022, cash reserves were $91.6 million, projected to fund operations into mid-2024.
Assembly Biosciences (ASMB) has announced the selection of ABI-5366 as a development candidate for its long-acting HSV-2 helicase inhibitor program. This selection marks a significant advancement since the company expanded its research focus beyond hepatitis B. The drug, designed for long-acting administration, shows favorable pharmacokinetics and potential for at least monthly dosing. Current HSV-2 therapies are partially effective, and ABI-5366 aims to enhance adherence and efficacy. The company plans to file with the FDA in the first half of 2024 and is eager to present more data at scientific conferences this year.
Carver Biosciences, a Boston-based biotech firm focused on CRISPR/Cas13 antivirals, has established its Scientific Advisory Board (SAB). Dr. Cameron Myhrvold will chair the SAB, with Dr. Uri Lopatin, Dr. Olivia Merkel, and Dr. Neville Sanjana joining as members. Dr. Lopatin brings significant experience from founding Assembly Biosciences (NASDAQ:ASMB) and Pardes Biosciences (NASDAQ:PRDS), having raised over $600 million for novel therapies. The new board aims to enhance Carver's pipeline and advance its clinical programs.
Assembly Biosciences (ASMB) reported promising interim results from two Phase 1 clinical trials for its HBV core inhibitors ABI-H3733 and ABI-4334. In the 50 mg cohort of ABI-H3733, six of eight patients achieved HBV DNA levels below quantification by day 21, marking a mean reduction of 3.1 logs. The ABI-4334 trial indicated a favorable pharmacokinetic profile supporting once-daily dosing. Both studies observed no serious adverse events, showcasing safety. A second cohort for ABI-H3733 is ongoing, with data expected in Q1 2023.
Assembly Biosciences (Nasdaq: ASMB) has initiated a Phase 1a clinical trial for its investigational core inhibitor ABI-4334, aimed at treating chronic hepatitis B virus (HBV). The trial, which has begun dosing healthy volunteers, evaluates the safety, tolerability, and pharmacokinetics of 4334. This next-generation treatment shows significantly enhanced potency against cccDNA formation compared to earlier inhibitors. Chronic HBV affects about 296 million people globally, leading to serious liver diseases. The trial results will support future development phases for 4334.
Assembly Biosciences (ASMB) announced its Q3 2022 financial results, revealing a net loss of $23.1 million ($0.48 per share). The company initiated a Phase 1a trial for ABI-4334, its next-generation core inhibitor, and plans to report Phase 1b data for ABI-H3733 by year-end. Research expenses decreased to $18.1 million due to the discontinuation of some projects. Cash reserves stand at $108.7 million, expected to fund operations until mid-2024. The company expanded its pipeline with new programs targeting genital herpes and transplant-associated herpesviruses.
